Form 8-K - Current report:
SEC Accession No. 0001193125-23-001236
Filing Date
2023-01-04
Accepted
2023-01-04 08:31:03
Documents
12
Period of Report
2023-01-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d367027d8k.htm   iXBRL 8-K 26791
  Complete submission text file 0001193125-23-001236.txt   149564

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA abos-20230103.xsd EX-101.SCH 2861
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE abos-20230103_lab.xml EX-101.LAB 17977
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE abos-20230103_pre.xml EX-101.PRE 11265
6 EXTRACTED XBRL INSTANCE DOCUMENT d367027d8k_htm.xml XML 3341
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40551 | Film No.: 23504447
SIC: 2836 Biological Products, (No Diagnostic Substances)